On the evening of August 24th, 2022, semiconductor manufacturer SMC International released their financial report for the first half of the year. The company's revenue totaled 5.65 billion yuan and their adjusted net profit amounted to 1.44 billion yuan.
On August 25th, Simo held a mid-year performance press conference for the year 2022. The Chairman and CEO Chen Zhiping, Vice President Qiu Lingyun, and CFO Wang Guisheng were in attendance.
Chen Zhiping, Chairman and CEO of Smoore Group, was quoted by the official website of the Electronic Cigarette Committee of the China Electronic Commerce Association.
After the meeting, 2FIRSTS obtained the main contents of the conference and arranged them as follows.
Business arrangement:
During the Q&A session, Chen Zhiping stated that in the foreseeable future, Smoore will only focus on these three main businesses: firstly, new types of tobacco, which is their major source of revenue and has vast market potential; secondly, beauty; and lastly, healthcare. The healthcare sector includes the treatment of lung diseases such as asthma and COPD with western medicine, as well as the research of traditional Chinese medicine.
Regarding the annual performance expectations:
Overall, Simona is optimistic about its long-term growth prospects. In terms of revenue, there has been a significant improvement in the overseas market compared to the first half of the year. As for performance expectations, Simona's forecast for the second half of the year is better than the first half.
Overseas Markets:
Semiconductor company Smoltech is projected to have better performance in the European and American markets in the second half of the year compared to the first. The European market is experiencing organized and rapid growth, while in the United States, Smoltech's majority clients are receiving PMTA certification due to the implementation of FDA regulations, positioning the company for a competitive edge.
4. Pricing Strategy:
The company's product pricing strategy remains unchanged. The reason for the increase in the proportion of low-margin products in the first half of the year is due to Somor's efforts in reducing costs for both themselves and their customers by increasing automation in their production lines. This has led to a decrease in gross profit margins in the first half of the year, but will ultimately lead to long-term benefits and more competitive and differentiated products for customers.
Healthcare Industry:
Chen Zhiping stated, "In the medical field, including the treatment of lung diseases such as asthma and chronic obstructive pulmonary disease using Western medicine, as well as research in traditional Chinese medicine, we have experience. We have proposed the concept of modernizing traditional Chinese medicine, using advanced technology to revitalize traditional Chinese medicine and scientifically prove its effectiveness.
Simulaids began laying the framework for their presence in the healthcare industry two years ago. In China, Simulaids has completed innovative certification applications for their medical nebulizing delivery devices and is currently pushing forward with product registration and sales planning. Additionally, Simulaids has established a medical research institute and wholly-owned subsidiary in the United States.
Technological Barrier:
Patents are a crucial element in the creation of technological barriers for semiconductor manufacturer, SMIC. Currently, SMIC has applied for a total of 4,337 patents worldwide, with 929 new applications submitted in the first half of this year. These new applications primarily focus on four areas: aerosol generation, various heating technologies, medical nebulization, and non-combustion heating.
Simoer's technical strengths are in materials research and process research.
Simoer hopes that their technological innovations can form a complete system (including heating elements, materials, processes, manufacturing, etc.), enhancing overall competitiveness.
Talent Barrier: In the first half of this year, semiconductor manufacturer SMIC opened 14 basic research institutes around the world, attracting numerous globally renowned scientists, hundreds of graduates from top universities, and many senior management talents. As of the end of June, the company had a total of 1,472 R&D experts, accounting for over 40% of its research staff.
To read more about Sumo Logic's release of its mid-term financial report, please click on the following headline link to be redirected:
Simo announced that only orders commissioned through the National Standard Technical Review Committee will be accepted. Here are ten important points to understand Simo's financial report for the first half of 2022.
Risk Warning and Disclaimer:
This article is based on the compilation of media interviews from the SMIC 2022 mid-year performance release conference. It has not been confirmed by SMIC officials.
This article is for internal industry research and exchange purposes only. It does not make any investment or brand recommendations and should not be used as a basis for any investment decisions.
This article is an original piece created by Shenzhen 2FIRSTS Technology Co., Ltd. The copyright and permission to use it belong to the company and no individual or entity is authorized to use it for commercial reprint, copying, or any other means of copyright infringement without permission. Any violation will result in legal action taken by the company.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
